everolimus

Generic: everolimus

Labeler: biocon pharma inc.
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name everolimus
Generic Name everolimus
Labeler biocon pharma inc.
Dosage Form TABLET, FOR SUSPENSION
Routes
ORAL
Active Ingredients

everolimus 2 mg/1

Manufacturer
Biocon Pharma Inc.

Identifiers & Regulatory

Product NDC 70377-090
Product ID 70377-090_38b19b37-504e-24ed-7dbc-8b9f9e3fda0a
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA217216
Listing Expiration 2027-12-31
Marketing Start 2026-01-14

Pharmacologic Class

Established (EPC)
kinase inhibitor [epc] mtor inhibitor immunosuppressant [epc]
Mechanism of Action
protein kinase inhibitors [moa] cytochrome p450 3a4 inhibitors [moa] cytochrome p450 2d6 inhibitors [moa] mtor inhibitors [moa]
Physiologic Effect
decreased immunologic activity [pe]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 70377090
Hyphenated Format 70377-090

Supplemental Identifiers

RxCUI
1308428 1308430 1308432
UPC
0370377092114 0370377090110 0370377091117 0370377091230 0370377090233
UNII
9HW64Q8G6G
NUI
N0000175605 N0000175076 N0000182141 N0000182137 N0000175625 N0000175624 N0000175550

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name everolimus (source: ndc)
Generic Name everolimus (source: ndc)
Application Number ANDA217216 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 2 mg/1
source: ndc
Packaging
  • 28 TABLET, FOR SUSPENSION in 1 BOTTLE (70377-090-11)
  • 4 BLISTER PACK in 1 CARTON (70377-090-23) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK
source: ndc

Packages (2)

Ingredients (1)

everolimus (2 mg/1)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "38b19b37-504e-24ed-7dbc-8b9f9e3fda0a", "openfda": {"nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "upc": ["0370377092114", "0370377090110", "0370377091117", "0370377091230", "0370377090233"], "unii": ["9HW64Q8G6G"], "rxcui": ["1308428", "1308430", "1308432"], "spl_set_id": ["5b809dfe-c076-07c5-207e-178c3f0d32d3"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "manufacturer_name": ["Biocon Pharma Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "28 TABLET, FOR SUSPENSION in 1 BOTTLE (70377-090-11)", "package_ndc": "70377-090-11", "marketing_start_date": "20260114"}, {"sample": false, "description": "4 BLISTER PACK in 1 CARTON (70377-090-23)  / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK", "package_ndc": "70377-090-23", "marketing_start_date": "20260114"}], "brand_name": "Everolimus", "product_id": "70377-090_38b19b37-504e-24ed-7dbc-8b9f9e3fda0a", "dosage_form": "TABLET, FOR SUSPENSION", "pharm_class": ["Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Decreased Immunologic Activity [PE]", "Kinase Inhibitor [EPC]", "Protein Kinase Inhibitors [MoA]", "mTOR Inhibitor Immunosuppressant [EPC]", "mTOR Inhibitors [MoA]"], "product_ndc": "70377-090", "generic_name": "Everolimus", "labeler_name": "Biocon Pharma Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Everolimus", "active_ingredients": [{"name": "EVEROLIMUS", "strength": "2 mg/1"}], "application_number": "ANDA217216", "marketing_category": "ANDA", "marketing_start_date": "20260114", "listing_expiration_date": "20271231"}